Drug Search Results
More Filters [+]

ABI-1968

Alternative Names: abi-1968, abi1968, abi 1968
Latest Update: 2021-01-13
Latest Update Note: Clinical Trial Update

Product Description

ABI-1968, a topical cream, in the treatment of cervical precancerous lesions in females without human immunodeficiency virus (HIV) infection. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03697226)

Mechanisms of Action: Apoptosis Stimulant

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Topical

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Antiva Biosciences
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for ABI-1968

Countries in Clinic: Australia

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Kidney Diseases|Pelvic Inflammatory Disease

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ACTRN12619001554156

P1

Recruiting

Kidney Diseases|Pelvic Inflammatory Disease

2019-12-01

Recent News Events